HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

M&A Heats Up As Major Players Eye New Markets, Categories

This article was originally published in The Rose Sheet

Executive Summary

The Estee Lauder Companies has its eyes peeled for potential acquisitions on the order of its MAC buy in the 1990s, making it one of a number of cosmetics firms with cash in hand and a view toward expansion. Kline & Company notes that the M&A market is heating up as the global economy improves and companies look to position themselves better in emerging markets and new product categories.

You may also be interested in...



L'Oreal's Q3 Driven By Luxe Gains, With China Cited As Engine

French beauty giant books luxury division sales growth of 8.9% to $2.35bn in its third quarter, and 13.2% growth to $7.16bn for the nine months ended Sept. 30. Increased consumption of luxury skin care and makeup in China has been a key driver of the firm's results in fiscal 2017, according to L'Oreal execs.

L’Oreal ‘Surfing’ Makeup Wave To Projected Strong Finish For FY 2016

Acquired brands NYX and Urban Decay are leading growth in L’Oreal’s makeup business, up 15% for the year to date. Strong demand for color cosmetics in the mass and luxury channels drove the firm’s Q3 sales, surpassing analyst expectations, if not L’Oreal’s.

L’Oreal Buys Back Shares From Nestle, Sells Galderma Stake

To finance a deal to purchase more than €6 billion of its own shares back from Nestle SA, L’Oreal SA has given up its half of skin-care company Galderma.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel